BeOne Medicines Ltd. (ONC)’s Combo Drug Shows Strong CLL Response

BeOne Medicines Ltd. (NASDAQ:ONC) has unveiled new data from the pivotal Phase 3 SEQUOIA trial at the 2025 ASCO Annual Meeting, highlighting the strong efficacy of BRUKINSA (zanubrutinib) both as monotherapy and in combination with venetoclax for frontline treatment of chronic lymphocytic leukemia (CLL), including high-risk patients with del(17p) and/or TP53 mutations. In Arm D, BRUKINSA plus venetoclax achieved a 24-month progression-free survival (PFS) rate of 92% and an overall response rate (ORR) of 97%.

BeOne Medicines Ltd. (ONC)’s BRUKINSA + Venetoclax Shows Strong Responses Across CLL Risk Groups

A close-up of a human hand holding a test tube with a blue liquid, representing the biopharmaceutical company’s research and development of new medicines.

Notably, 88% of high-risk patients remained progression-free at 36 months, and several were able to stop treatment early while maintaining remission, signaling the potential for time-limited therapy with sustained disease control. Arm C, which evaluated BeOne Medicines Ltd. (NASDAQ:ONC)’s BRUKINSA monotherapy in patients with del(17p), showed that 72% remained progression-free and 85% were alive at five years, marking the largest prospective study in this challenging population.

The safety profile was consistent with previous studies, with no new safety signals. These results reinforce BeOne Medicines Ltd. (NASDAQ:ONC)’s BRUKINSA’s versatility and potential to set new standards in CLL care, especially for patients with hard-to-treat genetic profiles.

While we acknowledge the potential of ONC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ONC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.